Navigation Links
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Date:7/27/2009

together are uniquely positioned to help medical providers and patients understand the clinical promise and economic value of denosumab."

"This pioneering treatment that Amgen has developed will be a strong addition to our biopharmaceuticals portfolio," commented Andrew Witty, CEO of GlaxoSmithKline. "The data for denosumab is very encouraging and we believe it will provide significant benefit and value to patients with postmenopausal osteoporosis and other bone disease conditions. Together with Amgen we are committed to increasing worldwide access to this medicine."

In July 2007, Amgen granted Daiichi Sankyo exclusive rights to develop and commercialize denosumab in Japan in PMO and oncology with the potential for additional indications. This arrangement remains in place.

About Denosumab

Denosumab is a fully human monoclonal antibody that targets RANK Ligand and is being investigated for its potential to prevent and treat a broad range of bone disease conditions including osteoporosis, bone metastases and their consequences, cancer treatment-induced bone loss due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that specifically inhibits RANK Ligand, an essential mediator of the cells that break down bone. With more than 19,000 patients in trials across indications worldwide, the denosumab development program is the largest ever initiated by Amgen. This broad and deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs.

Amgen has submitted marketing applications for denosumab in the United States, European Union, Canada, Switzerland, and Australia.

About Osteoporosis

Often referred to as the "silent epidemic," osteoporosis is a global problem that is
'/>"/>

SOURCE Amgen; GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 On Wednesday of last week ... use Redox Signaling molecules, became available for purchase in Australia ... "The way that RENU 28 works is, if you think ... of the rate of cellular renewal within your body. If ... of that rate of cellular renewal. What RENU 28 does ...
(Date:8/20/2014)... school history lessons often have it that American Indians ... cough, chicken pox, influenza and tuberculosis brought to the ... estimates vary, about 20 million people lived in the ... of them were killed by European diseases., But new ... State University and Johannes Krause of the University of ...
(Date:8/20/2014)... August 20, 2014 High performance ... apply the most complete climate and Earth system ... climate change issues. , Eight national laboratories, including ... the National Center for Atmospheric Research, four academic ... effort. Other participating national laboratories include Argonne, Brookhaven, ...
(Date:8/20/2014)... San Francisco, CA (PRWEB) August 20, 2014 ... Medicine Conference is being held on October 29-30 ... fresh perspectives from industry, academic and government researchers and ... remaining in the space. , In the twelve ... than one hundred therapies have been introduced with pharmacogenetic ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2
... hasn't felt a down economy at all. PHC Consulting is focused ... (laboratory clinical and research, physician call points, medical devices, pharmaceutical, etc). ... attributes that growth to a strong web presence. , ... ...
... BioTime’s wholly-owned subsidiary Embryome Sciences, Inc., have ... International Stem Cell Corporation (OTCBB:ISCO) through its ... jointly produce and distribute hundreds of new ... along with corresponding data and reagents. The ...
... /PRNewswire-FirstCall/ - Quest PharmaTech Inc.,(TSX-V: QPT), ("Quest" or ... I/II clinical study designed to investigate appropriate,treatment parameters ... for hair removal applications. The interim results represent ... targeted 100-patient clinical,trial., "The Phase I/II interim ...
Cached Biology Technology:Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point 2 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 2 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 3 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 4 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 5Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal 2Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal 3
(Date:8/21/2014)... Conn. , Aug. 21, 2014 Nxt-ID, ... the growing mobile commerce market, announced today that its ... common stock to be issued in its proposed underwritten ... approved for listing on The Nasdaq Capital Market, subject ... the common stock and warrants, and will trade under ...
(Date:8/21/2014)... ubiquitous skin fungus linked to dandruff, eczema and other ... to even further global reachesincluding Hawaiian coral reefs and ... vents. , A review in the scientific journal ... of the fungi of the genus Malassezia ... sequencing datasets from around the world. , University of ...
(Date:8/21/2014)... Nine researchers from Beth Israel Deaconess Medical Center (BIDMC ... World,s Most Influential Scientific Minds 2014," a comprehensive ... a web resource for science metrics and research performance ... the most influential "are performing and publishing work that ... their science," according to a Thomson Reuters statement. Researchers ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... creating a better way to see molecules at work in ... Learning and Memory and the MIT Department of Chemistry are ... also help further understanding of how synapses go awry in ... study will appear in the Oct. 7 issue of ...
... survival rates. Yet, one of the deadliest cancers in ... detect in its early stages. Now, researchers have ... shining diffuse light on cells swabbed from patients, cheeks. ... partial wave spectroscopic (PWS) microscopy--was able to differentiate individuals ...
... make life tougher for farmers and ranchers who live in ... why not turn the plants into fuel and make some ... alone could supply biomass far into the future, according to ... to fuel is an intriguing idea that,s being investigated by ...
Cached Biology News:MIT researchers develop a better way to see molecules at work in living brain cells 2Cheek swab may detect lung cancer 2Cheek swab may detect lung cancer 3Montana State, partners in 6 states consider converting invasive plants to fuel 2Montana State, partners in 6 states consider converting invasive plants to fuel 3Montana State, partners in 6 states consider converting invasive plants to fuel 4
... nucleotide structure called a ?cap? is ... naturally-occurring eukaryotic mRNAs and many viral ... a portion of the GTP present ... results in the synthesis of transcripts ...
... A modified nucleotide structure called a ... of most naturally-occurring eukaryotic mRNAs and ... Analog for a portion of the ... transcription reaction results in the synthesis ...
... structure called a ?cap? is present ... eukaryotic mRNAs and many viral RNAs. ... portion of the GTP present in ... in the synthesis of transcripts with ...
... Orbital Shakers have the durability ... stacked 3-high, and the uniformity ... "soft shake" applications. Heavily ... systems, our stackers are designed ...
Biology Products: